Latest News

Roche gets FDA priority review for atezolizumab

PD-L1 (programmed death-ligand 1), which is expressed on tumour cells and tumour-infiltrating immune cells, interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, atezolizumab can trigger activation of T cells, restoring their ability to effectively detect and attack tumour cells. © Genentech


by tg

Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.

Based on results of a single arm Phase II study, the FDA granted atezolizumab Priority Review in an additional type of advanced bladder cancer. While the agency granted accelerated market approval in May 2016 for the anti-PD-L1 antibody in patients who were treatment-refractive to platinum-based chemotherapy in neoadjuvant or adjuvant setting, the current priority review extends treatment options. Until April 2017, the agency will decide on the approval of atezolizumab in patients with bladder cancer not eligible for cisplatin chemotherapy (first-line treatment) or disease progression after 12 months of cisplatin therapy before or after surgery.

Roche’s supplemental biologics license application (sBLA) submission for atezolizumab is based on results from the Phase II IMvigor210 study. IMvigor210 is an open-label, single-arm Phase II study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic bladder cancer, regardless of PD-L1 expression. The primary endpoint of the study was objective response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival (OS), progression-free survival (PFS) and safety.

UK boosts AMR defenses with £30m PACE initiative

By bringing together funding, resources, and partnerships from its three notable partners Innovate UK, LifeArc, and Medicines Discovery Catapult...

BioNtech reports Car-T/mRNA booster study results at ESMO

Testing different dose levels of its adoptive cell therapy BNT.221-01, a combination of Claudin 6 (CLDN6)-targeted Car-T cells (derived from...

Mogrify Ltd extends Series A financing to $46m

The additional commitment of US$10m that results in US$46m raised was made by the new lead investors Astellas Venture Management and Parkwalk...

Pierre Fabre Laboratories acquires Vertical Bio

The acquisition of Vertical Bio AG for an undisclosed amount of money allows Pierre Fabre Laboratories to...

Sanofi licences vaccine against bacterial sepsis

Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

Aboleris Pharma bags €27.3m in Series A Financing

AbolerIS Pharma SA’s financing was led by  Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with...

AI protein specialist Cradle raises US$24m in Series A financing

Kindred Capital. and angel investors including Recursion CEO Chris Gibson and Tom Glocer, Lead Director, Merck participated it the US24m Series A...